An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

287

Participants

Timeline

Start Date

March 29, 2017

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
Refractory Schizophrenia
Interventions
DRUG

NaBen®

2000 mg/day or 1000 mg/day, twice daily

OTHER

Placebo

0 mg total, twice daily

Trial Locations (1)

91101

RECRUITING

For additional information regarding investigative sites for this trial, contact SyneuRx International Corp., Pasadena

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amarex Clinical Research

OTHER

lead

SyneuRx International (Taiwan) Corp

INDUSTRY